Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, investors reacted to this by bidding the biotech company's stock up by almost 6%. That was far higher than the 0.7% lift of the S&P 500 index that day. The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting minimal residual disease (MRD), a cancer disorder in which a relatively small number of cancer cells remain in the body -- and thus present a threat -- after medical treatment. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool